Amniotics AB announced that the board of directors has resolved to appoint PhD Marcus Larsson as new Chief Executive Officer of Amniotics. Marcus Larsson is a specialist in pediatrics, PhD in clinical physiology and one of the founders of Amniotics. He is also one of the inventors of Amniotics' patented technology to extract neonatal Mesenchymal Stem Cells (MSC) for the treatment of serious disease states.

Marcus Larsson has been a member of the Company's board of directors since the beginning and will remain as a board member in addition to his role as CEO. In connection with Marcus Larsson's appointment as new CEO, Kåre Engkilde leaves his current position as the Company's CEO.